iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond?

Brendan Coffey, The Motley Fool

Sat, August 8, 2026 astatine 11:22 AM CDT 5 min read

Investors choosing betwixt iShares Global Healthcare ETF (NYSEMKT:IXJ) and State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) indispensable measurement the high-growth imaginable of specialized U.S. biotech against a much stable, dividend-paying planetary healthcare portfolio.

Healthcare investors often take betwixt the stableness of established planetary giants and the high-growth imaginable of emerging biotechnology. This examination examines however the broad, planetary scope of the iShares money differs from the concentrated, equal-weighted U.S. absorption recovered successful the State Street portfolio.

Snapshot (cost & size)

Beta measures terms volatility comparative to the S&P 500; beta is calculated from monthly returns implicit the disposable money past (up to 5 years). The 1-yr instrumentality represents full instrumentality implicit the trailing 12 months. Dividend output is the trailing-12-month organisation output arsenic of the adjacent of trading connected August 6.

The State Street SPDR S&P Biotech ETF is somewhat much affordable with a 0.35% disbursal ratio. However, the iShares Global Healthcare ETF offers a importantly higher payout, with a output spread of 1.05 percent points implicit its peer.

Performance & hazard examination

What's wrong

The iShares Global Healthcare ETF holds 110 positions, providing vulnerability to planetary equities wrong the pharmaceutical, biotechnology, and aesculapian instrumentality industries. Its largest positions see Eli Lilly and Co (NYSE:LLY) astatine 10.3%, Johnson & Johnson (NYSE:JNJ) astatine 7%, and Abbvie Inc (NYSE:ABBV) astatine 5%. The money is designed for investors seeking wide assemblage sum with little volatility than niche sub-sectors. It was launched successful 2001. iShares Global Healthcare ETF has paid $1.44 per stock implicit the trailing 12 months, which connected its caller ~$101.3 stock terms works retired to a 1.4% yield.

The State Street SPDR S&P Biotech ETF tracks the S&P Biotechnology Select Industry Index utilizing a typical sampling method crossed 153 holdings. Its apical holdings see Apogee Therapeutics Inc (NASDAQ:APGE) astatine 1.7%, Oruka Therapeutics Inc (NASDAQ:ORKA) astatine 1.5%, and Dianthus Therapeutics Inc (NASDAQ:DNTH) astatine 1.4%. Because it uses a modified equal-weighting system, it provides important vulnerability to small- and mid-cap maturation stocks alternatively than conscionable manufacture titans. It was launched successful 2006. State Street SPDR S&P Biotech ETF has paid $0.57 per stock implicit the trailing 12 months, which connected its caller ~$154.5 stock terms works retired to a 0.4% yield.